Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... , June 30, 2015 First Choice ... to the Astanza Duality and is the only clinic ... offering professional tattoo removal treatments. The practice has recently ... Removal brand to showcase their focus in the ... residents better results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... Calif., Jan. 26, 2012  Cardica, Inc. (Nasdaq: CRDC ... its fiscal second quarter ended December 31, 2011, on Monday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details ...
... LONDON, Jan. 26, 2012  The IP & Science ... with Brazil,s Institute for Applied Economic Research (IPEA). ... and Policies for Innovation, Regulation and Infrastructure (DISET) ... suite of products, supplying them with generic pharmaceutical ...
Cached Medicine Technology:Cardica to Announce Fiscal 2012 Second Quarter Financial Results on Monday, February 6, 2012 2Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Opportunities in the Generic Drug Landscape 2
(Date:6/30/2015)... Madre, CA (PRWEB) , ... June 30, 2015 ... ... the company’s first UHMS approved 40-hour Introduction to Hyperbaric Medicine Course. Clinicians from ... packed weekend of hyperbaric medicine curriculum. , Wound care and hyperbaric medicine ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to announce it’s own Debby Mann, CPC, RCC, ROCC, Coding Documentation and Education ... with the Special Recognition Award for her contribution to the RBMA Coding Subcommittee. ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Trenton Health Team ... the first Medicaid Accountable Care Organizations (ACO) in the State, serving the greater Trenton ... , The Trenton Health Team ACO draws on the collaborative structure of THT, bringing ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... premier event and tradeshow, taking place July 29 to August 1. Retail Management ... , ThoughtSpot is a four-day event for independent community pharmacies, where ...
(Date:6/30/2015)... ... , ... The American Lung Association in California announced its new partnership with ... and clean air advocates included San Diego County Supervisor Ron Roberts, Dr. Atul Malhotra ... Sullivan, founder and president of Sullivan Solar Power. , For every solar power ...
Breaking Medicine News(10 mins):Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 3Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3
... Diabetes mellitus is a metabolic disorder characterized ... carbohydrate metabolism, and is associated with a ... Vascular changes in diabetes lead to increased ... to atherosclerosis,retinopathy, end-stage renal disease, debilitating neuropathies, ...
... of graft failure when male organs donated to females, ... Women who receive kidneys from males have a higher ... gender should be considered when choosing donor matches, ... Hospital Basel analyzed data on 195,516 people in Europe ...
... July 4 celebrations to the pros , , FRIDAY, July ... creating glittering showers of sparks and earth-rumbling booms that ... produce their own thrills, but mainly for young boys ... the danger. , "The natural predisposition for kids is ...
... online pharmacy has gone live, with a full range of products. ... it safely, securely, and in the privacy and comfort of their own ... ... many months of careful planning, the newest online pharmacy Licensed RX, at ...
... Boston University School of Medicine (BUSM) and Boston Medical ... violence (IPV) to their clinicians of any type did ... in a primary care or obstetrics/gynecology setting received the ... Biomedical Central Public Health Journal , also conclude that ...
... cost, number of false positives, study says , , THURSDAY, ... screenings for heart disorders in competitive athletes would improve ... and save lives, say Italian researchers. , In the ... days from an undetected cardiovascular disorder, according to background ...
Cached Medicine News:Health News:Gender Plays Role in Kidney Transplant Outcomes 2Health News:On Independence Day, Think Fireworks Safety First 2Health News:On Independence Day, Think Fireworks Safety First 3Health News:Licensed-Rx Goes Live 2Health News:Disclosing violence to primary care or obestetrics/gynecology physicians most beneficial 2Health News:Screening Athletes Could Cut Sudden Cardiac Death Risk 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: